Pioneering cellular medicines for women’s health

We’re developing off-the-shelf cell therapies for high-impact women’s diseases, with lead programs in ovarian cancer, triple negative breast cancer and endometriosis.

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.

Learn more about us

Some of our partners

Latest news

Cartherics shareholders Thao and Luyen Nguyen at the June 2019 Board Meeting …….

By Christine Filippis / June 24, 2019
Cartherics shareholders Thao and Luyen Nguyen at the June 2019 Board Meeting with Cartherics Chairman Bob Moses and CEO Alan Trounson celebrating...
Read More

Australian Biotechnology “REALITIES” : From the Laboratory to the Marketplace

By Christine Filippis / June 7, 2019
Cartherics’ Chairman Bob Moses has over 40 years of executive experience in life science companies. You name it, he’s been...
Read More

Science and Technology priorities – Election 2019

By Christine Filippis / May 8, 2019
MEDIA RELEASE 8 May 2019 Parties use science to set themselves apart .... The major parties have laid out their science...
Read More